The Federal Antimonopoly Service (FAS) of Russia for the first time, on the basis of a government decree, set a maximum selling price for the imported drug bromocriptine and sent the decision to the Ministry of Health.
The drug is used for Parkinson’s disease, pituitary dysfunction, as well as for the treatment of female infertility.
The procedure for compulsory re-registration of maximum selling prices for vital and essential medicines was established by a decree of the Government of Russia on December 16, 2019.
Pharmaceutical manufacturers are required to submit applications for mandatory re-registration of the prices of reference drugs by February 18, 2020. Revised maximum selling prices for drugs will enter into force within five months after the issuance of the relevant order of the Ministry of Health.
It is planned that the price update for essential medicines will be completed by the end of 2020.